AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting. by Liu, AY et al.
Oncotarget4276www.oncotarget.com
AGR2, a unique tumor-associated antigen, is a promising 
candidate for antibody targeting
Alvin Y. Liu1, Adelle D. Kanan1, Tomasz P. Radon2, Siama Shah2, Mark E. Weeks2, 
Julie M. Foster2, Jane K. Sosabowski2, Laurent Dumartin2 and Tatjana Crnogorac-
Jurcevic2
1 Department of Urology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA
2 Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
Correspondence to: Alvin Y. Liu, email: aliu@uw.edu
Tatjana Crnogorac-Jurcevic, email: t.c.jurcevic@qmul.ac.uk
Keywords: pancreatic cancer; eAGR2; chimeric antibody; prostate cancer; tumor localization
Received: March 05, 2019     Accepted: April 21, 2019     Published: July 02, 2019
Copyright: Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC 
BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are 
credited.
ABSTRACT
Anterior gradient 2 (AGR2), a protein disulfide isomerase, shows two subcellular 
localizations: intracellular (iAGR2) and extracellular (eAGR2). In healthy cells that 
express AGR2, the predominant form is iAGR2, which resides in the endoplasmic 
reticulum. In contrast, cancer cells secrete and express eAGR2 on the cell surface. 
We wanted to test if AGR2 is a cancer-specific tumor-associated antigen. We utilized 
two AGR2 antibodies, P3A5 and P1G4, for in vivo tumor localization and tumor growth 
inhibition. The monoclonal antibodies recognized both human AGR2 and mouse Agr2. 
Biodistribution experiments using a syngeneic mouse model showed high uptake of 
P3A5 AGR2 antibody in xenografted eAgr2+ pancreatic tumors, with limited uptake 
in normal tissues. In implanted human patient-derived eAGR2+ pancreatic cancer 
xenografts, tumor growth inhibition was evaluated with antibodies and Gemcitabine 
(Gem). Inhibition was more potent by P1G4 + Gem combination than Gem alone or 
P3A5 + Gem. We converted these two antibodies to human:mouse chimeric forms: 
the constructed P3A5 and P1G4 chimeric mVLhCκ and mVHhCγ (γ1, γ2, γ4) genes 
were inserted in a single mammalian expression plasmid vector, and transfected into 
human 293F cells. Expressed human:mouse chimeric IgG1, IgG2 and IgG4 antibodies 
retained AGR2 binding. Increase in IgG yield by transfected cells could be obtained 
with serial transfection of vectors with different drug resistance. These chimeric 
antibodies, when incubated with human blood, effectively lysed eAGR2+ PC3 prostate 
cancer cells. We have, thus, produced humanized anti-AGR2 antibodies that, after 
further testing, might be suitable for treatment against a variety of eAGR2+ solid 
tumors.
INTRODUCTION
Based on current figures, it is estimated that by 
2040 there will be close to 30 million new cancer cases 
worldwide (http://gco.iarc.fr/tomorrow/home). Solid 
tumors are by far the most common, including lung, 
breast and prostate cancers. Pancreatic cancer, incidence 
of which is increasing, is particularly aggressive with a 
relatively short span between diagnosis and death.
AGR2 (anterior gradient 2) is an adenocarcinoma 
antigen expressed by many solid tumor types. In prostate, 
AGR2 is overexpressed in cancer cells compared with 
normal luminal cells, and a majority of primary prostate 
tumors are AGR2 positive [1], This pattern is similarly 
found in pancreatic [2, 3], oral [4], and breast cancers 
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[5]. AGR2 is also highly expressed in non-small cell lung 
cancer (NSCLC) where high expression is associated with 
poor survival [6].
We have previously demonstrated the expression 
and role of AGR2 in initiation of pancreatic cancer [7], 
and that premalignant lesions of both the prostate and 
pancreas show AGR2 expression [3, 8]. AGR2 also 
plays a role in cancer spread [3, 4, 9]. Bone and soft 
tissue metastases in advanced prostate cancer show 
high AGR2 expression [10], and in pancreatic cancer, 
metastatic growth could be inhibited by targeting AGR2 
[11]. Therefore, due to almost ubiquitous expression in 
solid tumors, expression in premalignant lesions and its 
involvement in metastatic disease, AGR2 represents an 
attractive target for cancer therapy. Importantly, while it 
is localized to the endoplasmic reticulum (intracellular 
iAGR2 [12]) in normal cells, AGR2 is secreted and found 
on the surface (extracellular eAGR2) of cancer cells [2, 
8, 13–16]. Normal cells would thus likely be unaffected 
by anti(α)-AGR2 reagents. This property makes AGR2 a 
unique tumor-associated antigen (TAA).
One of the successful approaches in cancer therapy 
that targets TAA is the use of anti-TAA monoclonal 
antibodies and their engineered derivatives. For example, 
Herceptin (trastuzumab) is a well-known humanized 
monoclonal antibody used in the treatment of HER2-
positive cancers [17], and Erbitux (cetuximab), a pan-
erbB inhibitor, is used for cancers expressing different 
levels and subclasses of EGFRs [17] including NSCLC 
[18]. Kadcyla (trastuzumab emtansine, ɑ-HER2, -EGFR, 
-CD340) and Adcetris (brentuximab vedotin, ɑ-CD30) are 
examples of antibody-drug conjugates (ADC) approved 
to treat recurrent breast cancer or some hematological 
malignancies, respectively. Gemtuzumab ozogamicin 
(ɑ-CD33) is a recombinant humanized IgG4κ antibody, 
which is conjugated to a cytotoxic antitumor antibiotic 
directed against the CD33 antigen present on leukemic 
myeloblasts in acute myeloid leukemia [19]. All of these 
antibodies have received federal approval, and are used as 
effective cancer therapeutics. Recently, an ADC ɑ-PSMA 
was shown to produce clinically relevant decline in 
prostate-specific antigen (PSA) and circulating tumor cell 
counts in metastatic castration resistant prostate cancer 
[20]. However, lack of widespread application of many 
ADC treatments can be attributed to surface expression of 
these TAA in normal cells [21–23] leading to unavoidable 
side effects.
For clinical application, mouse antibodies are 
converted to human:mouse chimeric or humanized forms 
to reduce anti-mouse response; more importantly, mouse 
antibodies interact poorly with human effector cells 
and protein factors to mediate cell killing. Therapeutic 
antibodies promote target cell death through antibody-
dependent cell-mediated cytotoxicity (ADCC), which is 
effected by immune cells through FcγR binding [24], while 
complement-dependent cytotoxicity (CDC) is triggered by 
binding of complement proteins to the Fc domain to form 
an attack complex [25]. In our previous work, radiolabeled 
cancer cells were exposed to antibodies and human 
serum or peripheral blood leukocytes [26, 27]. In CDC, 
the chimeric antibodies generated higher response at all 
complement titers than the mouse antibodies. In ADCC, 
the chimeric antibodies lysed a greater fraction of cancer 
cells at lower concentrations. Cell killing was specific 
because ADCC was not observed with cells lacking the 
targeted antigen [26, 27].
Using recombinant AGR2 as immunogen, we 
generated two ɑ-AGR2 monoclonal antibodies: P3A5 
(IgG2a) and P1G4 (IgG1) [13]. We used several assays 
to ensure they recognize the native antigen [13]. P1G4 
and P3A5 in ELISA could detect cancer-secreted AGR2 
in voided urine from 1.26 to 181 pg/mL in a cohort 
of samples [13]. A commercial diagnostic company, 
MagArray, showed experimentally that our antibody 
pair detected AGR2 with better sensitivity than any 
other available antibodies (Dr. Heng Yu, personal 
communication). Both of these monoclonal antibodies 
(mAb) were therefore selected for humanization. Our 
study demonstrates the possibility that these ɑ-AGR2 
reagents could be clinically useful in treating eAGR2+ 
cancer while sparing iAGR2+ healthy cells.
RESULTS
Cancer cell surface expression of AGR2
We have previously demonstrated the surface 
expression of AGR2 on human breast and pancreatic 
cancer cells [3]. Figure 1A shows cell surface detection 
by flow cytometry of Agr2 on DT6606 mouse pancreatic 
cancer cells using P3A5 and P1G4 antibodies. These cells 
were then used for tumor localization in vivo.
Localization of ɑ-AGR2 mAb in mice implanted 
with Agr2+ tumors
Figure 1B shows the efficiency of radiolabeling, 
injected radioactivity values for P3A5 and control IgG 
(specific activity of radiolabeled P1G4 was suboptimal, 
and was not used). Images in Figure 1C of the implanted 
DT6606 tumor in syngeneic C57BL/6 mice show specific 
uptake of P3A5 from 24 to 48 hours post injection.
Tumor growth inhibition by ɑ-AGR2
The in vivo anti-tumor activity of P1G4 and P3A5 
antibodies was assessed using patient-derived pancreatic 
cancer xenograft (PDX) models. Tumor-bearing mice 
were treated with P1G4 (P1) or P3A5 (P3) alone or in 
combination with standard of care drug Gemcitabine 
(Gem) up to week 6 vs. Gem alone (Figure 2A). Antibody 
monotherapy showed no anti-tumor activity in the immune 
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compromised hosts. Combination of P3A5 with Gem 
showed no additive activity compared to Gem alone. 
However, combination of P1G4 with Gem showed a 
stronger reduction in tumor volume as well as delayed 
tumor regrowth compared to Gem alone, even several 
weeks after discontinuation of treatment (Figure 2A). 
Figure 2B shows the tumors extracted from mice culled 
at 6 weeks due to tumor sizes reaching the maximum 
threshold (1 cm3) in the IgG, P1 and P3 groups. Figure 
2C shows the percentage survival of mice in different 
treatment groups. Notably, by week 12, three of five mice 
in Gem-only group reached the tumor burden threshold, 
while this was the case in only one of four remaining P1 
+ Gem mice.
The anti-tumor activity of P1G4 in combination 
with Gem was confirmed in a follow up experiment (data 
not shown). Figure 2D shows the immunohistochemistry 
results: AGR2 immunoreactivity confirmed that all tumors 
were AGR2+. Ki67 staining indicated less proliferation in 
the P1G4 + Gem-treated tumors. An abundant infiltration 
of T cells was observed in tumors treated with Gem or 
P1G4 + Gem. No visible histological changes were 
detected in the internal organs (liver, spleen, stomach, 
intestine, colon, and pancreas).
Generation of human:mouse chimeric P3A5 and 
P1G4 antibodies
The human C-domain modules C
γ
 and C
κ
 were 
joined to the mouse VH and VL modules in a single plasmid 
vector (Figure 3). Reverse transcriptase-polymerase chain 
reaction (RT-PCR) of cells transfected with plasmid pN4 
showed equivalent transcript levels for neo (encoding 
G418 resistance), L chain and H chain (Figure 4A). The 
neo and L chain were transcribed from one promoter, 
while the H chain from another. The in-frame ATG before 
the start codon in the P3A5 mouse VL proved inhibitory for 
translation as no secreted immunoglobulin was detected in 
the culture media of pN4. A primer containing a canonical 
Kozak sequence was used to replace that part of the 5’ 
noncoding segment (p7-2). The same sequence was also 
used for the VH module (p13-1). This proved successful 
Figure 1: Cell surface expression of AGR2. (A) Fluorescence shifts of P1G4- and P3A5-labeled DT6606 primary pancreatic cancer 
cells (vs. control IgG) indicate that eAgr2 is present on the cell surface. Two cytograms are shown. (B) The table shows labeling of 
antibodies. (C) The representative images show DT6606 tumor uptake of radiolabeled P3A5 (marked by *) at 24 h and 48 h post-injection. 
No significant label could be detected in iAgr2-positive normal tissues.
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(see below). There was no notable difference in protein 
expression level for the H chain with either the native or 
the artificial Kozak sequence.
Expression of functional IgG by transfected cells
The cell-free culture media supernatant was assayed 
for ɑ-AGR2 activity by ELISA. Figure 4B showed that the 
chimeric IgG1 antibodies produced by plasmids p7-2 and 
p13-1 were similar to P3A5 in AGR2 binding as indicated 
by the color intensity of the chromogen detector. For 
comparison, the negative controls were 293F media and 
media of p6-2 with a defective L construct. Media from 
culture passages showed that immunoglobulin synthesis 
continued indicating integration of the transgenes into 
the host genome. G418 selection was no longer required, 
therefore this toxic compound is not necessary in IgG 
preparations for clinical use. ELISA (Figure 4C) showed 
that spin filtration was effective in concentrating the 
immunoglobulins (150 kDa). In addition, chimeric IgG1, 
like P3A5, detected similarly different levels of AGR2 
produced by several prostate cancer PDX LuCaP lines 
(Figure 4D).
AGR2 binding activity of chimeric IgG2 (p16-
1) and IgG4 (p17-1) was also demonstrated by ELISA 
(Supplementary Figure 1). Several clones of either isotype 
tested showed similar levels of activity. The IgG3 isotype 
was not obtained as the C
γ3
 sequence was not detected in 
the white blood cell cDNA used for cloning IgG genes.
The P1G4 constructs, p40-1 and p50-1, were also 
successful in producing the corresponding IgG1 transcripts 
in 293F cells (Figure 4E). The P1G4 chimeric IgG1 showed 
similar AGR2 binding activity as P1G4 (Figure 4F).
Increased IgG production of bsrR/neoR cells
Figure 5 compares production of human IgG 
by 293F cells transfected with p20-6 (bsrR) and cells 
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transfected with p20-6 followed by p13-1 (neoR). The 
resultant double drug resistant cells were shown positive 
by RT-PCR for bsr and neo. Similar numbers of cells 
were plated in 6-well plates, and the cell-free media was 
collected after 3 days. ELISA showed that more AGR2-
binding activity was observed in p20-6/p13-1 than p20-
6. AGR2-binding activity was higher in p20-6/p13-1 
than p20-6 when 10 μL and 1 μL of cell-free media from 
cultures containing 106 cells were compared.
Anti-tumor effect of chimeric antibodies on PC3 
prostate cancer cells
Spin concentrated chimeric IgG was used on eAGR2+ 
PC3 cells with serum donated from healthy volunteers. 
Cells plated in culture wells were incubated in human 
serum with added AGR2 antibodies. Figure 6 shows that in 
the well with human serum alone, there was no observable 
effect on cell viability. Likewise, no effect was seen in the 
well with mouse P3A5. In the well with chimeric γ1, γ2, 
and γ4, cell growth was inhibited as indicated by large 
surface areas of the well devoid of cells while clusters of 
pyknotic cells were seen in suspension after 3 days.
DISCUSSION
Due to frequent expression in common solid tumors, 
expression in premalignant lesions, circulating tumor 
cells and metastases [3-8], AGR2 represents an exciting 
cancer-specific target. In tumor localization experiments, 
we demonstrated the accumulation of radiolabeled mAb 
in the pancreatic tumors. The fortuitous cross-reactivity 
Figure 2: Tumor growth inhibition by drug in combination with antibodies. (A) PDX tumor growth in mice in response to 
treatment with ɑ-AGR2 P1 (P1G4) and P3 (P3A5), alone or in combination with Gem demonstrate that antibodies alone produced minimal 
effect; the best tumor suppression was achieved in the P1 + Gem group. Tumor volume is indicated on the y-axis, and treatment duration in 
weeks on the x-axis. Differences in tumor volumes between P1 + Gem vs. Gem were statistically significant (*) at weeks 3-5. (B) Tumors 
extracted at week 6 from the different groups are compared. (C) The Kaplan–Meier plot shows the percentage survival (y-axis) of mice 
across all six groups (in weeks on the x-axis). (D) Representative immunohistochemistry images on tumor tissue samples from IgG control, 
P1, Gem and P1 + Gem confirm expression of AGR2 in all tumors. Ki67 staining indicated that the tumors treated with Gem still had high 
proliferation rate, which was limited in P1 + Gem-treated tumors. The tumors from Gem- and P1 + Gem-treated mice exhibited abundant 
CD3+ T cell infiltration. Size bars = 200 μm. Inserts at the top right of individual images are at 200x magnification.
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between human AGR2 and mouse Agr2 suggests that 
a similar result could be obtained in pancreatic cancer 
patients with minimal targeting of iAGR2-expressing 
healthy cells. Furthermore, since the generated antibodies 
could recognize murine Agr2, one would expect severe 
deleterious effects on multiple organs with abundant 
circulating ɑ-AGR2/Agr2 after treatment. However, 
this was not observed and the internal organs examined 
showed no histological evidence of toxicity, as did the 
organs of mice in the production of hybridomas [13].
The combination of anti-cancer drugs and antibodies 
has been shown to be clinically useful in treating lung 
cancer [28]. At present, we do not know the precise 
mechanism in the enhancement of Gemcitabine inhibition 
of tumor growth by P1G4 mAb, and the reason why 
P3A5 was not as efficient. This could be related to the 
different epitopes recognized by the antibodies, need for 
increased therapeutic doses or a longer treatment regimen. 
Additionally, whether drug + other TAA antibodies would 
produce a similar or improved effect in the pre-clinical 
pancreatic cancer model remains to be determined. 
Interestingly, we observed CD3+ lymphocytes in our 
treated mice, which was unexpected. It is likely that these 
could be extrathymic T cells, as athymic nude mice carry 
neither conventional T cells nor NKT cells of thymic 
origin. However, NK1.1-TCRint cells of extrathymic 
origin can be found in the liver and other immune organs, 
and may also infiltrate tumors [29].
A humanized ɑ-AGR2 (18A4Hu) and its murine 
version (18A4) alone were reported to have inhibitory 
effect on AGR2+ ovarian cancer xenograft SK-OV-3 
[30]. This result is somewhat perplexing (although not 
Figure 3: Plasmid vector for P3A5 H and L chain expression. The joined mouse VH module (EcoRV-ApaI) and human Cγ1 
module (ApaI-BamHI), as well as the joined mouse VL module (BamHI-HindIII) and human Cκ module (HindIII-AvrII) are shown. The H 
and L chain genes are cloned in the orientation depicted in plasmid p13-1. Gene expression control elements are identified. PacI is used to 
linearize the plasmid for transfection. Plasmid p20-6 has bsr instead of neo. Plasmids p40-1 and p50-1 (not shown) are the corresponding 
neo and bsr vectors for chimeric P1G4.
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Figure 4: Immunoglobulin expression in transfected 293F cells. (A) RT-PCR analysis for neo (560 bp), L (720 bp) and H 
(1420 bp) chains in cells transfected with plasmid pN4 at passage 4 (p4) to show that the transgenes were being transcribed at equivalent 
levels. (B) ELISA result shows AGR2 binding by IgG1 from transfected 293F cells (in triplicate). The color intensity indicates similar 
binding affinity between the IgG1 constructs p7-2 and p13-1 vs. P3A5. Background consists of untransfected 293F and p6-2, which is a 
non-productive construct. Detection is by either HRP anti-human IgG for the transfected cell media or HRP anti-mouse IgG2a for P3A5. 
(C) ELISA shows IgG isolation by spin filtration. Background level was detected in the 100 μL flow-through well (4th) vs. the three wells 
(1st – 3rd) containing different amounts of the filtrate/retentate. (D) Histogram representation of ELISA data shows comparable binding 
between 293F-synthesized human IgG and P3A5 in tissue digestion media of LuCaP lines (147, 35CR, 86.2, 105) with different levels of 
AGR2 expression. p12-1 is a defective construct, and served as negative control. Absorbance units are indicated on the y-axis. (E) RT-PCR 
analysis of 293F/p40-1 P1G4 chimeric detected transcripts for bsr (420 bp), VL, VLCκ, VH, and VHCγ1. (F) The histogram bars show AGR2 
binding activities detected in media supernatant of p40, p50, and p40 clones A1-A6 (absorbance units on the y-axis). The positive control is 
mouse P1G4 and the negative control 293F cells. “Early” and “later” indicate media harvested during early and late passages, respectively, 
of cultures after drug selection.
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discussed in the paper) because in nude mice with no 
immunity, antibodies by themselves would have no 
significant effect on xenograft growth as shown by our 
mAb in the absence of Gem.
In prostate cancer, cancer-associated antigens PSA, 
PSMA, PAP, PSCA, MUC1 and PAGE/GAGE have been 
used to stimulate T cell-mediated immunity [31]. Lack of 
consistent success could be partly due to some of these 
antigens being secreted molecules or not prostate-specific 
[21, 32]. In contrast, AGR2 expression differs between 
cancer and normal cells in subcellular localization, eAGR2 
vs. iAGR2. We have previously shown that normal cells 
in lung and bladder do not secrete AGR2 as we found 
only background levels of AGR2 in serum samples using 
sensitive targeted proteomics [33]. A somewhat contrary 
result reported significant amounts of AGR2 in blood, 
but these were based on the use of polyclonal AGR2 
antibodies [34], and have not been validated by multiple 
large-scale proteomics studies (archived in PeptideAtlas). 
Furthermore, normal urine contains little AGR2 even 
though the entire urothelium is positive for AGR2 [16]. 
This research did not set out to quantify the percentage 
of cancer-secreted AGR2 that might be targeted by 
ɑ-AGR2. However, it is an important factor that should be 
established in future studies.
In addition to pancreatic cancer, the lysis of 
eAGR2+ PC3 cancer cells in vitro shows that targeting 
AGR2 could also prove to be effective against prostate 
cancer. The common expression of AGR2 in other solid 
tumors suggests that such treatments may also be effective 
in other cancer types, and in the orthotopic setting, but 
these still remain to be established. Similarly, the anti-
metastatic activity of ɑ-AGR2, as recently shown in 
the lung metastasis mouse model [35], warrants further 
investigation. Cancer-specific cell surface expression of 
eAGR2 makes cancer vaccination an exciting possibility, 
where a primed immune response could potentially 
eliminate any newly arisen eAGR2+ cancer cells.
Figure 5: Increased IgG production from serially transfected 293F cells. (A) Cell-free media supernatant from increasing 
amounts of cells seeded in culture wells were assayed for AGR2-binding activity. The source of AGR2 was provided by LNCaP cells 
transfected with AGR2 (based on the same plasmid vector). Absorbance units are shown on the y-axis. (B) The volumes of media supernatant 
obtained from similar numbers of cells were assayed. The negative control is media from untransfected 293F cells. Absorbance units are 
shown on the y-axis. (C) Transcript levels of bsr, neo, L and H chains, B2M were detected in the doubly transfected clone A3.
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The pVITRO plasmid and 293F cells proved to be 
a good system for immunoglobulin synthesis given that 
both L and H chains can be inserted in one vector. In the 
transfected cells, the L and H chain proteins were correctly 
processed, assembled, and secreted. The IgG molecules 
can be readily concentrated by spin filtration after growth 
in serum-free media. For protein expression, only the 
Kozak box outside the coding region is sufficient. The 
native Kozak sequences are as efficient as the canonical 
sequence. The strategy of serial transfection using 
different drug selection was successful in enhancing the 
yield of antibodies. A third plasmid with hygromycin 
selection might increase production even further, and 
economically, it is fairly inexpensive to obtain antibodies 
from transfected 293F cells. The chimeric IgG1 and IgG2 
isotypes can substitute for the murine IgG1 (P1G4) and 
IgG2a (P3A5) in ELISA. We are now in the process of 
cloning the human IgG3 to complete the human gamma 
immunoglobulin repertoire [36]. As P3A5 and P1G4 bind 
to different epitopes, they might also act synergistically, 
which also remains to be determined.
In summary, we present further evidence that 
AGR2 is a promising therapeutic target and report on the 
production of two humanized antibodies that could, after 
further evaluation, be employed for therapeutic purposes.
MATERIALS AND METHODS
Flow analysis of AGR2 cell surface expression
Mouse ɑ-AGR2 monoclonals P1G4 and P3A5 were 
purified from growth media of their respective hybridoma 
clones [13]. The mouse Agr2+ primary pancreatic cancer 
cell line DT6606 (PdxCre/LSL-KrasG12D) [37, 38], were 
harvested by trypsin/EDTA, resuspended in DMEM, 0.1% 
BSA, 0.1% sodium azide and incubated with antibodies 
on ice 45 min. Bound antibodies were detected with dye-
conjugated anti-mouse IgG2a. Labeled cells were scanned 
on a BD FACSAria II Cell Sorter (BD Biosciences, San 
Jose, CA) and analyzed using CellQuest Pro software (BD 
Biosciences).
Figure 6: Treatment of AGR2+ PC3 cells by chimeric antibodies. Shown are photomicrographs of plated eAGR2+ PC3 cells 
incubated in human serum (top left); serum with P3A5 (top right); serum with IgG1, IgG2, IgG4 (bottom left and right). 
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Antibody labeling and biodistribution
The antibodies were conjugated on their lysine 
residues using p-SCN-Bn-CHX-A”-DTPA (Macrocyclics, 
Plano, TX, USA) [39]. Briefly, the antibodies were 
dialyzed against 1L 0.05 M HEPES, pH 8.5 containing 
5 g Chelex 100 (Bio-Rad, Hercules, CA, USA) using 
Maxi GeBAflex-tube dialysis tubes (MWCO 8 kDa, 
Gene Bio-Application, Israel). CHX-DTPA was then 
added in 5-fold molar excess and reacted for 2 h at 
room temperature. Conjugation solutions were purified 
by dialysis into 0.4 M ammonium acetate pH 5.5. 111In 
radiolabeling was carried out at 37° for 30 min at pH 
5, and analysed by iTLC-SG (Agilent, Santa Clara, CA, 
USA). For tumor localization, C57BL/6 mice carrying 
DT6606 tumors were injected i.v. with radiolabeled 
antibodies and imaged at 24 and 48 h post injection by 
SPECT/CT (Bioscan, Santa Barbara, CA, USA).
Tumor growth inhibition
For in vivo testing, CD1 female mice were 
implanted with pancreatic PDX (6 groups of 6 mice each) 
subcutaneously in both flanks as described previously [40]. 
Each animal was treated by intraperitoneal injection of 
antibodies at 5 mg/kg of body weight twice a week for four 
weeks; Gemcitabine (G6423 Gemcitabine hydrochloride 
>98% HPLC, Sigma, St. Louis, MO, USA) was 
administered at 100 mg/kg once a week for 6 weeks. Six 
experimental groups were: 1. IgG control; 2. Gem only; 3. 
P1 only; 4. P3 only; 5. P1 + Gem; 6. P3 + Gem. Tumors 
were measured at implantation, and then once every 
week, and animal weights recorded twice a week. After 
treatment cessation, mice were continuously monitored to 
week 12. After sacrifice, the liver, pancreas, spleen, lungs, 
stomach, intestine and colon were collected and examined 
histologically. All animal studies were performed in 
compliance with the UK Animals (Scientific Procedures) 
Act 1986 and the Code of Practice for the Housing and 
Care of Animals used in Scientific Procedures (Home 
Office, UK).
Immunohistochemistry
For immunohistochemical analysis, tissue blocks 
were serially cut into 5 μm sections, which were first 
stained by hematoxylin and eosin (H&E) to assess 
histology, and then for AGR2 (C1313 Santa Cruz Biotech, 
Santa Cruz, CA, USA (1 = 30)), Ki67 (2746/1 Epitomics, 
Burlingame, CA, USA (1 = 6000)) and CD3 (A0452 Dako, 
Santa Clara, CA, USA (1 = 200)). Immunohistochemistry 
was performed following protocols for the Ventana 
Discovery System automated platform (Roche, 
Switzerland). Histology was reviewed using the digital 
program Pannoramic Viewer (3DHistech, Hungary).
Human immunoglobulin cDNA
Blood samples were drawn from consented donors, 
and partitioned on density gradients. White blood cells 
were collected, lysed for RNA isolation and cDNA 
synthesis. The resultant cDNA was checked by PCR for 
B2M (β2-microglobulin). The human gamma heavy chain 
constant module was obtained by PCR with primers: Cγ-5 
GGTCACCGTCTCTTCAGCCTCCACCAAGGGCCCAT
CG with ApaI restriction enzyme site and Cγ-3 GAATTCG
GATCCTCATTTACCCGGAGACAGGGAGAGGCTCTT
CTG. The human kappa light chain constant module was 
obtained by primers: Cκ-5 CTCACTTTCGGCGGAGGGA
CCAAGCTTGAGATN with HindIII site and Cκ-3 GAAT
TCGGATCCCTAACACTCTCCCCTGTTGAAGCTCTT
TGTGACG. The products were each inserted into plasmid 
pCR2.1 (Thermo Fisher, Waltham, MA, USA). DNA 
sequenciplasmid pCR2.1 (Thermo Fisher, Waltham,ng 
showed that γ1, γ2 and γ4 constant domains were cloned 
– both γ1 and γ4 have a SacII site, while γ4 has an EcoRI 
site, γ2 has no SacII or EcoRI.
P3A5 and P1G4 mouse immunoglobulin cDNA
P3A5 and P1G4 hybridoma cells were lysed for 
cDNA synthesis. The heavy chain variable module (IghV1-
37) was obtained by primers: P3A5 H-5 GTCCTCGGTA
CCGATATCGAACACACTGACTCCAACTATGGGA
TGGACGTGGATC and P3A5 H-3 CACACAGGGGC
CAGTGGATAGACCGATGGGCCCTTTGTGCTGGC
NNNN (with ApaI site). The light chain variable module 
(IgκV6-15) was obtained by primers P3A5 L-5 GAATT
CGAAGATATCAGATCAGCATGGGCATCAAGATG
GAGTCACAGACTCAG and P3A5 L-3 CAGCATCA
GCCCGTTTTATTTCAAGCTTGGTCCC (with HindIII 
site). The primer sequences were based on previous DNA 
sequence analysis of P3A5 immunoglobulin cDNA. P3A5 
mRNA was reverse transcribed with primers of mouse 
C
κ
 and C
γ2a
 matching sequences a short distance beyond 
the V/C junctions. The same primers were used for DNA 
sequencing of the cDNA products. The L-5 sequence 
contains an in-frame ATG upstream of the start codon 
(which could be due to a misread of DNA sequence data of 
the cDNA 5’ end). Primer L-5c GAATTCGAAGGATCCC
AAGCCACCATGGAGTCACAGACTCAGGTCTTG was 
used to remove this ATG and introduce a consensus Kozak 
box (gccRccAUGG). Primer P3A5 H-5a GAATTCGAAG
ATATCCAAGCCACCATGGGATGGACGTGGATCTTT
CTCTTC was used to introduce the canonical Kozak box 
to the heavy chain construct. Similarly, mouse C
κ
 and C
γ1
 
primers were used to determine the V domain sequences 
of P1G4. Primers for cloning P1G4 VH and Vκ were: heavy 
chain (IghV1-52) H-5 GAATTCGAAGATATCCAAGCC
ACCATGGGATGGAGCTGCATCATCCTC and H-3 GA
TGGGCCCTTTGTGCTGGCTGAGGAGACTGTGAGA
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GTGGTGCC; light chain (IgκV4-68) L-5 GAATTCGAA
GGATCCCAAGCCACCATGGATTTTCAAGTGCAGA
TTTTC and L-3 CAGCATCAGCCCGTTTATTTCAAGC
TTTGTCCCCGAGCCGAACGTG. The canonical Kozak 
box was used in both chains.
Construction of expression plasmids
The mouse VH and human CH modules were joined 
at the ApaI site; the mouse VL and human CL modules were 
joined at the HindIII site. For mammalian cell expression, 
plasmid pVITRO1-neo-mcs (InvivoGen, San Diego, 
CA, USA) was used, which contains modules of SV40 
and CMV enhancers, mEF1 and rEF1 promoters, SV40 
transcription termination and poly-adenylation [41]. The 
chimeric heavy chain EcoRV-BamH1 module was inserted 
into the EcoRV and BglII sites of mcs2, and the chimeric 
light chain BamHI-AvrII module was inserted into the 
BamHI and AvrII sites of mcs1 to obtain plasmid pN4 
(γ1). Other constructs (see also Supplementary Materials) 
included p6-2 (L-5a, γ1), p7-2 (L-5c, γ1), p12-1 (L-5a, 
H-5a, γ1), p13-1 (L-5c, H-5a, γ1), p16-1 (L-5c, γ2), and 
p17-1 (L-5c, γ4). pVITRO1-blasti (InvivoGen) was used 
to replace the neo gene of p13-1 with the bsr (encoding 
blasticidin resistance) gene via XbaI/EcoRI digestion to 
produce plasmid p20-6. This construction was used to test 
whether serial transfection – p13-1 followed by p20-6 or 
p20-6 followed by p13-1 – would increase the yield of 
secreted IgG1 by the resultant neoR/bsrR 293F cells.
P1G4 chimeric plasmids were constructed by 
replacing the P3A5 H and L chain modules in p20-6 with 
the respective P1G4 H and L chain modules: p40-1bsrR 
(BamHI-AvrII L module) and p50-1bsrR (BglII/BamHI-
AvrII L module) (Supplementary Materials). Plasmids for 
IgG2, IgG4, and neoR version were also generated.
Gene transfection
Plasmid DNA linearized by PacI was used in 
transfection of human embryonic kidney fibroblast 
HEK293F by electroporation (AMAXA nucleofactor 
program A-024, Lonza, Switzerland). At 2-3 days post-
transfection, the cells were placed in media with 1 mg/
mL G418 (Mediatech, Manassas, VA, USA) for selection. 
The transfected G418-resistant cells were weaned from 
FBS by serially culture from 10%, 5%, 2% to serum-
free media (FreeStyle 293, Thermo Fisher). Cloning 
was accomplished by picking colonies with pipetor. 
RNA was isolated and analyzed by RT-PCR with primer 
pairs of mouse V 5’ and human C 3’ (see above) as well 
as neo5: GCAGCTGTGCTCGACGTTGTCACTG 
and neo3: CAGAGTCCCGCTCAGAAGAACTCGTC 
using “hot start” with 35 cycles of 94°, 30 s; 57°, 30 s; 
72°, 60 s. For p20-6 transfection, blasticidin (Thermo 
Fisher) was used at 5 μg/mL. Both G418 and blasticidin 
concentrations were pre-determined. Primers for bsr were 
bsr5: ATGAAGACCTTCAACATCTCTCAGA and bsr3: 
TTAGTTCCTGGTGTACTTGAGGGG.
In serial transfection, 293F cells were first 
transfected by p20-6, and blasticidin resistant clones were 
selected. IgG-producing bsrR cells were then transfected 
by p13-1, and cultured in G418. Cell-free media 
supernatants of the resultant cells: 293F/p20-6bsrR/p13-
1neoR were assayed for secreted human IgG1. The double 
drug resistant cells were grown on serum- and drug-free 
media for large-scale production.
ELISA of chimeric antibodies
For P3A5, each well of 96-well plates was coated 
with 0.2 μg P1G4 in 100 μL PBS overnight followed by 
rinsing with PBS-0.05% Tween, and blocking with 1% 
BSA-PBS. Cell-free prostate LuCaP xenograft tissue 
collagenase digestion media containing secreted AGR2 
[42, 43], diluted 1/10, was added. P3A5 (0.2 μg) or media 
(100 μL) of transfected 293F cells were used for detection, 
followed by goat anti-mouse IgG2a-HRP or goat anti-
human IgG-HRP (Southern Biotech, Birmingham, AL, 
USA), where appropriate, diluted at 1:2000 in 1% BSA-
PBS followed by 1-step ABTS (Thermo Fisher). Wells 
were scanned at λ = 415 nm after 5-30 min [13]. For 
P1G4, the wells were coated with P3A5. Goat anti-mouse 
IgG1-HRP for positive control and goat anti-human IgG-
HRP were used for detection.
Spin concentration of immunoglobulin
Positive transfected cells were grown in 100 mL 
serum-free media without drugs. The cell-free media were 
centrifuged in 15-mL aliquots through 30K spin cartridges 
(Millipore, Burlington, MA, USA) in 50 mM NH4HCO3, 
4K, 60 min to <1 mL in volume. ELISA was used to 
measure IgG in the concentrate.
In vitro testing of cancer cell lysis
For anti-tumor effect, eAGR2+ PC3 cells [13] were 
incubated with human serum plus antibodies. The cells 
were cultured in a 24-well plate till about 75% confluent. 
Human serum was used from fresh blood donations after 
centrifugation to remove blood cells, and 50 μL was 
added to the wells. Fifty μL each of spin concentrated 
P3A5 IgG1, IgG2, IgG4 were added for incubation at 37°. 
Photomicrographs of the culture were taken.
Statistical analysis
The Mann-Whitney U test was used to compare 
the P1 + Gem combination group to Gem-only group. 
Statistical analysis was performed and graphs plotted 
using the GraphPad Prism software and P values of <0.05 
were considered statistically significant.
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